E. Ohman J or Asset Management AB Has $4.28 Million Stock Position in Stryker Corporation $SYK

E. Ohman J or Asset Management AB lessened its holdings in Stryker Corporation (NYSE:SYK) by 16.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,186 shares of the medical technology company’s stock after selling 2,468 shares during the period. E. Ohman J or Asset Management AB’s holdings in Stryker were worth $4,283,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of Stryker by 0.8% in the third quarter. Vanguard Group Inc. now owns 33,773,399 shares of the medical technology company’s stock worth $12,485,012,000 after buying an additional 272,828 shares during the last quarter. State Street Corp increased its holdings in shares of Stryker by 1.0% during the 2nd quarter. State Street Corp now owns 14,956,732 shares of the medical technology company’s stock valued at $5,929,765,000 after acquiring an additional 150,204 shares during the last quarter. Alliancebernstein L.P. increased its holdings in shares of Stryker by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 6,338,050 shares of the medical technology company’s stock valued at $2,342,987,000 after acquiring an additional 741,542 shares during the last quarter. Norges Bank bought a new position in shares of Stryker in the 2nd quarter valued at approximately $1,882,173,000. Finally, Legal & General Group Plc lifted its holdings in Stryker by 4.4% in the 3rd quarter. Legal & General Group Plc now owns 2,303,290 shares of the medical technology company’s stock worth $851,457,000 after purchasing an additional 96,662 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Transactions at Stryker

In other news, Director Ronda E. Stryker sold 250,000 shares of the business’s stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total transaction of $90,730,000.00. Following the transaction, the director owned 2,457,331 shares in the company, valued at approximately $891,814,566.52. The trade was a 9.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 5.20% of the stock is owned by corporate insiders.

Stryker Stock Performance

Shares of NYSE SYK opened at $332.48 on Tuesday. Stryker Corporation has a 12 month low of $328.23 and a 12 month high of $404.87. The company has a market cap of $127.24 billion, a P/E ratio of 39.58, a P/E/G ratio of 1.96 and a beta of 0.85. The business’s 50 day moving average is $362.68 and its two-hundred day moving average is $365.29. The company has a quick ratio of 1.21, a current ratio of 1.89 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, January 29th. The medical technology company reported $4.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The business had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter last year, the company posted $4.01 earnings per share. Stryker’s quarterly revenue was up 11.4% on a year-over-year basis. On average, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date is Tuesday, March 31st. Stryker’s dividend payout ratio (DPR) is currently 41.90%.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SYK shares. Citizens Jmp raised Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 target price for the company in a research report on Friday, December 19th. Barclays restated an “overweight” rating and issued a $469.00 price objective on shares of Stryker in a research note on Monday, February 2nd. Piper Sandler reaffirmed an “overweight” rating on shares of Stryker in a report on Tuesday, January 27th. Evercore set a $390.00 target price on shares of Stryker in a research note on Monday, January 5th. Finally, William Blair reiterated an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Fourteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $427.50.

Key Stryker News

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Company statement that the cybersecurity incident has been contained and reported remediation is underway, reducing immediate operational disruption risk. Stryker Addresses and Contains Recent Cybersecurity Incident
• Positive Sentiment: Company reports progress in restoration efforts and that operations are stabilizing — supports expectations for limited revenue disruption if recovery continues. Stryker reports progress in restoration efforts after cyberattack, operations continue to stabilize
• Neutral Sentiment: Market coverage and peer comparisons may reframe investor valuation assumptions (Envista and Intuitive Surgical comparisons highlight relative growth and margin dynamics). NVST or SYK: Which Is the Better Value Stock Right Now? Intuitive Surgical vs. Stryker: Which Surgical Tech Stock Leads?
• Neutral Sentiment: Corporate housekeeping: Stryker announced its 2026 Annual Meeting of Shareholders — routine but relevant for governance-minded investors. Stryker announces Annual Meeting of Shareholders
• Negative Sentiment: Independent reporting warns attackers — including state-linked groups — are increasingly targeting enterprise systems to disrupt operations and extract leverage; this elevates the potential for future incidents, regulatory scrutiny, and remediation costs. Stryker Cyberattack Highlights Criminal Focus on Enterprise Systems

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.